Literature DB >> 26074443

Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase.

Enrico Maria Zardi1, Domenico Maria Zardi2, Diana Chin2, Chiara Sonnino3, Aldo Dobrina4, Antonio Abbate3.   

Abstract

Patients with advanced liver cirrhosis may develop a clinical syndrome characterized by a blunted contractile responsiveness to stress and/or altered diastolic relaxation, called "cirrhotic cardiomyopathy." This syndrome, which is initially asymptomatic, is often misdiagnosed due to the presence of symptoms that characterize other disorders present in patients with advanced liver cirrhosis, such as exercise intolerance, fatigue, and dyspnea. Stress and other conditions such as liver transplantation and transjugular intrahepatic portosystemic shunt (TIPS) may unmask this syndrome. Liver transplantation in this group of patients results in a clinical improvement and can be a cure for the cardiomyopathy. However, post-transplant prognosis depends on the identification of cirrhotics with cardiomyopathy in the pre-transplant phase; an early diagnosis of cirrhotic cardiomyopathy in the pre-transplant phase may avoid an acute onset or worsening of cardiac failure after liver transplantation. Since a preserved left ventricular ejection fraction may mask the presence of cirrhotic cardiomyopathy, the use of newer noninvasive diagnostic techniques (i.e. tissue Doppler, myocardial strain) is necessary to identify cirrhotics with this syndrome, in the pre-transplant phase. A pre-transplant treatment of heart failure in cirrhotics with cardiomyopathy improves the quality of life in this phase and reduces the complications during and immediately after liver transplantation. Since specific therapies for cirrhotic cardiomyopathy are lacking, due to the absence of a clear understanding of the pathophysiology of the cardiomyopathy, further research in this field is required.
Copyright © 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cirrhotic cardiomyopathy; Echocardiography; Liver cirrhosis; Liver transplantation

Mesh:

Year:  2015        PMID: 26074443     DOI: 10.1016/j.jjcc.2015.04.016

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  18 in total

1.  Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart.

Authors:  Moreshwar S Desai; Bhoomika Mathur; Zeena Eblimit; Hernan Vasquez; Heinrich Taegtmeyer; Saul J Karpen; Daniel J Penny; David D Moore; Sayeepriyadarshini Anakk
Journal:  Hepatology       Date:  2016-11-29       Impact factor: 17.425

Review 2.  Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes.

Authors:  Francesco Vizzutti; Filippo Schepis; Umberto Arena; Fabrizio Fanelli; Stefano Gitto; Silvia Aspite; Laura Turco; Gabriele Dragoni; Giacomo Laffi; Fabio Marra
Journal:  Intern Emerg Med       Date:  2020-01-09       Impact factor: 3.397

3.  Preoperative dobutamine stress echocardiography in patients undergoing orthotopic liver transplantation.

Authors:  Krishna K Patel; Laura Young; William Carey; Kathryn A Kohn; Richard A Grimm; L Leonardo Rodriguez; Brian P Griffin; Milind Y Desai
Journal:  Clin Cardiol       Date:  2018-07-17       Impact factor: 2.882

4.  QTc prolongation in patients of cirrhosis and its relation with disease severity: An observational study from a rural teaching hospital.

Authors:  Abhinav Bhardwaj; Sandeep Joshi; Ruby Sharma; Sakshi Bhardwaj; Rishabh Agrawal; Nitin Gupta
Journal:  J Family Med Prim Care       Date:  2020-06-30

5.  Protective role of cardiac-specific overexpression of caveolin-3 in cirrhotic cardiomyopathy.

Authors:  So Yeon Kim; Kang Ho Kim; Jan M Schilling; Joseph Leem; Mehul Dhanani; Brian P Head; David M Roth; Alice E Zemljic-Harpf; Hemal H Patel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-21       Impact factor: 4.052

Review 6.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

Review 7.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

Review 8.  Current Concepts of Cirrhotic Cardiomyopathy.

Authors:  Manhal J Izzy; Lisa B VanWagner
Journal:  Clin Liver Dis       Date:  2021-03-10       Impact factor: 6.126

9.  Cardiovascular mortality in liver and kidney transplant recipients: A retrospective analysis from a single institution.

Authors:  Zrinka Sertić; Tomislav Letilović; Tajana Filipec Kanižaj; Mladen Knotek; Irzal Hadžibegović; Inga Starovečki; Helena Jerkić
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

10.  The Pre-Transplant Profile of Cardiovascular Risk Factors and Its Impact on Long-Term Mortality After Liver Transplantation.

Authors:  Renata Główczyńska; Michalina Galas; Anna Witkowska; Urszula Ołdakowska-Jedynak; Joanna Raszeja-Wyszomirska; Krzysztof Krasuski; Piotr Milkiewicz; Marek Krawczyk; Krzysztof Zieniewicz; Grzegorz Opolski
Journal:  Ann Transplant       Date:  2018-08-21       Impact factor: 1.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.